Cognitive & nootropic

Cerebrolysin

CereFPF-1070EVER Pharma Cerebrolysinporcine brain peptide preparation

Cerebrolysin is a porcine-brain-derived mixture of low-molecular-weight peptides and free amino acids studied for purported neurotrophic and neuroprotective effects, approved as a medicine in some countries but not by the US FDA.

Overview

Cerebrolysin is a parenteral preparation made by enzymatic breakdown of purified porcine (pig) brain proteins. It is not a single molecule but a standardized mixture — the great majority is free amino acids, with the remainder a fraction of biologically active low-molecular-weight peptides (under ~10 kDa). Reported composition figures vary across sources (commonly cited as roughly 75–85% free amino acids and 15–25% peptides). Because of this heterogeneity it has no single molecular formula, molecular weight, or PubChem compound record; the substance-level CAS registry number 12656-61-0 is used to identify the preparation.

Its proposed mechanism is neurotrophic: preclinical and laboratory reports describe it mimicking or upregulating endogenous neurotrophic factors (e.g. BDNF, GDNF, NGF, CNTF) with downstream effects on neurogenesis, synaptic plasticity, and neuroinflammatory signaling. No single active component or defined molecular target has been characterized.

Cerebrolysin is marketed as a prescription medicine by EVER Pharma (EVER Neuro Pharma, Austria) in over 50 countries — including Austria, Germany, Russia, China and South Korea — for indications such as acute stroke, traumatic brain injury and dementia. It is not approved by the US FDA and is not a licensed medicine in the UK, so in this UK reference context it is documented strictly as research material rather than a recommended therapy.

The human evidence base is large but contested. A 2020 Cochrane systematic review (Ziganshina et al.) of acute ischaemic stroke concluded that Cerebrolysin probably makes little to no difference to death, while moderate-quality evidence indicated an increase in non-fatal serious adverse events; the reviewers also noted that several included trials involved the manufacturer. Separate meta-analyses in traumatic brain injury (e.g. a 2023 Brain Sciences review) have reported statistically significant changes in Glasgow Outcome Scale scores but no effect on mortality. These conflicting signals are why the evidence here is framed as mixed and not as established efficacy.

Mechanism, evidence & status

Cerebrolysin is a standardized mixture of low-molecular-weight peptides (under ~10 kDa) and free L-amino acids enzymatically derived from purified porcine brain tissue. Its proposed action is neurotrophic: laboratory and preclinical reports describe it mimicking and upregulating endogenous neurotrophic factors such as BDNF, GDNF, NGF, and CNTF, with associated effects on neurogenesis, synaptic plasticity, and anti-inflammatory signaling. Because it is a heterogeneous mixture, no single active molecule or defined molecular target has been characterized.

Human evidence: Mixed and contested human clinical data; large but heterogeneous trial base with conflicting meta-analyses
Regulatory status: Marketed as a prescription medicine by EVER Pharma in over 50 countries (e.g. Austria, Germany, Russia, China, South Korea) for indications such as stroke and dementia. NOT approved by the US FDA for any indication, and not a licensed medicine in the UK. As a porcine-brain-derived mixture with no single defined active ingredient, it has no US NDA and is treated here strictly as reference material, not a recommended therapy.

Research applications

Investigated in clinical research for neurorecovery after acute ischaemic stroke (subject of a Cochrane systematic review).
Studied as an adjunct in traumatic brain injury research, with meta-analyses reporting changes in Glasgow Coma/Outcome scores but no mortality effect.
Explored in research on vascular dementia and Alzheimer's disease as a putative neurotrophic agent.
Used as a model compound in preclinical neuroscience research on neurotrophic-factor signaling, neurogenesis, and synaptic plasticity.

Safety considerations

Reported adverse effects in the product literature include injection-site reactions, nausea, dizziness, headache, and sweating; it is described as not recommended for people with epilepsy, severe kidney disease, or hypersensitivity to its constituents.
The 2020 Cochrane review (Ziganshina et al.) reported moderate-quality evidence of an increase in non-fatal serious adverse events with Cerebrolysin in acute ischaemic stroke, while finding it probably makes little to no difference to death.
It is a biological extract of animal (porcine) brain origin, raising theoretical concerns around batch-to-batch variability and biological-source contamination; only parenteral pharmaceutical-grade product has been studied.
Not evaluated or approved by the FDA or MHRA; safety and efficacy outside its approved markets are not independently established.

References